QuidelOrtho Corporation

QDEL

$14.05

+0.86%

2026-09-04 11:59:59 EDT+$0.12

Healthcare

Medical - Specialties

NASDAQ

Active Trading

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company ...

Supply Chain of QDEL

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Shenzhen Lifotronic Technology Co., Ltd.

Shanghai Runda Medical Technology Co., Ltd.

Various single-source raw material and component suppliers

Antibody and biological reagent producers (industry-level)

Specialty chemical and membrane manufacturers (industry-level)

Shenzhen Lifotronic Technology Co., Ltd.

SHSE:688389

Strategic supply partner for immunoassay analyzer platforms (high-throughput and low-to-mid volume). Long-term agreement signed February 2026 to supply multiple analyzer platforms with broad assay menu.

Shanghai Runda Medical Technology Co., Ltd.

SHSE:603108

Joint venture partner (since Dec 2022) to develop and manufacture assays in China for QuidelOrtho's VITROS immunodiagnostic platform. Provides local market assay development and manufacturing capabilities.

Thermo Fisher Scientific Inc.

NYSE:TMO

Partnership for VITROS QC Solutions (MAS Quality Controls). Also Fisher Scientific arm serves as a distribution channel for QuidelOrtho products. Provides quality control materials for VITROS analyzers.

Various single-source raw material and component suppliers

QuidelOrtho relies on single or sole source suppliers for key raw materials, components, and sub-assemblies per its 10-K. Includes antibodies, reagents, nitrocellulose membranes for lateral flow tests, plastic molded components, electronic assemblies, and packaging. Specific supplier names not publicly disclosed in filings.

Antibody and biological reagent producers (industry-level)

Tier 2 suppliers providing antibodies, antigens, and biological reagents used in QuidelOrtho's immunoassay and rapid test products. The IVD industry sources from specialty biochemical suppliers globally.

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

McKesson Corporation

Cardinal Health, Inc.

Henry Schein, Inc.

Thermo Fisher Scientific / Fisher Scientific

Hospitals and Hospital Networks (US & global)

Clinical Reference Laboratories

Blood Banks, Plasma Centers, and Donor Screening Organizations

Retail Pharmacies, Urgent Care Centers, and Physician Offices

McKesson Corporation

NYSE:MCK

Broad distribution partner for Point of Care products (QuickVue, Sofia) reaching clinics, urgent care, physician offices, and retail pharmacies across the US.

Cardinal Health, Inc.

NYSE:CAH

Distribution partner for Point of Care and rapid diagnostic tests. Cardinal Health was named a key partner for distributing QuickVue OTC COVID-19 tests. Also named Clinical Diagnostic Supplier of the Year by Cardinal Health.

Henry Schein, Inc.

NASDAQ:HSIC

Distribution partner for QuidelOrtho Point of Care testing products (QuickVue, Sofia) to medical practitioners, clinics, and physician offices.

Thermo Fisher Scientific / Fisher Scientific

NYSE:TMO

Distribution channel for QuidelOrtho diagnostic assays and instruments via Fisher Scientific catalog and e-commerce platform. Also QC solutions partner for VITROS platform.

Hospitals and Hospital Networks (US & global)

Core end-customer segment for Labs (VITROS chemistry/immunoassay systems) and Transfusion Medicine (blood bank analyzers/reagents). Includes large integrated delivery networks (IDNs) and community hospitals. Highly fragmented customer base with no single customer exceeding 10% of revenue per 10-K disclosure.

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

Abbott Laboratories

Danaher Corporation

Bio-Rad Laboratories, Inc.

Siemens Healthineers AG

Abbott Laboratories

NYSE:ABT

Primary direct competitor in Point of Care (BinaxNOW, ID NOW), immunoassay (ARCHITECT), and molecular diagnostics. Abbott is the largest diversified diagnostics peer and serves as the best bellwether for the IVD industry trends that drive QuidelOrtho's end-markets.

Danaher Corporation

NYSE:DHR

Major IVD competitor via Beckman Coulter (immunoassay/chemistry) and Cepheid (molecular). Danaher's Diagnostics segment is a pure-play proxy for the diagnostics end-market. Its supply chain sophistication and operating margin trajectory are reference points.

Bio-Rad Laboratories, Inc.

NYSE:BIO

Direct competitor in blood typing/transfusion medicine and immunoassay quality controls. Bio-Rad also supplies raw materials (antibodies, reagents) to the broader IVD industry, serving as both competitor and potential supplier proxy.

Siemens Healthineers AG

ETR:SHL

Major competitor in clinical chemistry, immunoassay, and Point of Care diagnostics. Siemens Healthineers trades on the German exchange and provides a European IVD industry proxy.

Geographic

Region-level exposures that can distort the supply network.

Geographic

China

United States (California, New York, Ohio)

Japan

Shenzhen Lifotronic Technology Co., Ltd.

Shanghai Runda Medical Technology Co., Ltd.

QuidelOrtho Manufacturing Facilities (San Diego, Carlsbad, CA; Rochester, NY; Athens, OH)

Ortho-Clinical Diagnostics K.K. (QuidelOrtho Japan subsidiary)

China

Manufacturing and supply chain partnership dependency

Shenzhen Lifotronic Technology Co., Ltd.SHSE:688389Strategic supply agreement for immunoassay analyzer platforms (Feb 2026). China-based supplier creates concentration risk from trade tensions, export controls, or IP transfer concerns.

Shanghai Runda Medical Technology Co., Ltd.SHSE:603108Joint venture for VITROS assay development and manufacturing in China. Creates exposure to China regulatory changes, trade policy, and operational risks.

United States (California, New York, Ohio)

Domestic manufacturing concentration

QuidelOrtho Manufacturing Facilities (San Diego, Carlsbad, CA; Rochester, NY; Athens, OH)NASDAQ:QDELPrimary manufacturing footprint concentrated in the US. Subject to domestic labor costs, regulatory risks (FDA), natural disaster risks (California earthquake/wildfire exposure), and logistics disruptions.

Japan

Regional headquarters and legacy Ortho supply chain

Ortho-Clinical Diagnostics K.K. (QuidelOrtho Japan subsidiary)NASDAQ:QDELRegional HQ in Tokyo (Shinagawa) with manufacturing/supply chain presence from legacy Ortho Clinical Diagnostics Japan operations. Exposure to Japan-specific regulatory and economic risks.

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Other

Critical

Single and sole-source supplier dependency for key raw materials and components. Per the 2024 10-K, the company relies on a limited number of suppliers for critical inputs including antibodies, reagents, membranes, electronic components, and molded plastics. Any supply disruption could materially impact manufacturing.

Customer

Medium

Diagnostics industry customer concentration risk is mitigated (no single customer >10% of revenue per 10-K), but the company is exposed to hospital and lab consolidation trends among large IDNs and reference laboratory chains, which could increase pricing pressure.

Equipment

High

Reliance on proprietary VITROS analyzer installed base (~20,000+ units globally). Reagent rental/recurring revenue model means any disruption in analyzer manufacturing or service parts could impact reagent pull-through revenue.

Foundry

High

Dependency on contract manufacturers for certain sub-assemblies and components. Per 10-K, the company relies on a small number of contract manufacturers, making it vulnerable to capacity constraints or quality issues.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

Labs (Clinical Chemistry & Immunoassay - VITROS platform)

54.0%

$1.5B

Largest segment drives demand for VITROS analyzers, reagents, and QC materials. Heavy reliance on proprietary reagent supply agreements and single-source component suppliers for analyzer manufacturing.

Transfusion Medicine (Blood bank & Donor Screening)

18.0%

$0.5B

Requires specialized immunohematology reagents, column agglutination technology components, and blood typing antisera. Legacy Ortho business with mature supply chain for ORTHO Workstation and BioVue consumables.

Point of Care (Sofia, QuickVue, Triage rapid tests)

17.0%

$0.5B

High-volume consumables business dependent on lateral flow membrane supplies (nitrocellulose), antibody pairs, plastic cassettes, and packaging. Subject to respiratory seasonality. Distribution-intensive segment requiring broad channel partners.

Molecular Diagnostics (Lyra, Savanna, LEX Diagnostics)

11.0%

$0.3B

PCR-based and molecular testing requiring specialized reagents, enzymes, primers/probes, and thermocycler components. Savanna platform development discontinued in June 2025; strategy pivoted to LEX Diagnostics acquisition (completed April 2026).

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer